

BIOLIDICS LIMITED
(Company Registration No.: 200913076M)
(Incorporated in the Republic of Singapore)

BIOMEDICS LABORATORY PTE. LTD. – GRANT OF APPROVAL BY SINGAPORE'S MINISTRY OF HEALTH FOR THE PROVISION OF MEDICAL MICROBIOLOGY (MOLECULAR MICROBIOLOGY) SERVICES, INCLUDING SARS-COV-2 POLYMERASE CHAIN REACTION TESTING FOR CORONAVIRUS DISEASE 2019

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**" and together with its subsidiaries, the "**Group**") is pleased to announce that the Group's wholly-owned subsidiary, Biomedics Laboratory Pte. Ltd. ("**Biomedics**") has, on 29 December 2021, been granted the approval by Singapore's Ministry of Health ("**MOH**") to provide medical microbiology (molecular microbiology) services, including SARS-CoV-2 polymerase chain reaction ("**PCR**") testing for coronavirus disease 2019 ("**COVID-19**") (the "**MOH Approval**").

Pursuant to the grant of the MOH Approval, and subject to Biomedics performing satisfactorily in the interlaboratory comparison of a testing panel prepared by the National Public Health Laboratory, Biomedics shall be permitted to receive patient samples for COVID-19 PCR testing (the "**Testing Services**").

The MOH Approval is not expected to have a material impact on the financial performance of the Group for the current financial year ending 31 December 2021, and barring unforeseen circumstances, given the ongoing COVID-19 pandemic, and subject to Biomedics being able to successfully secure sales for the Testing Services, the Company expects the MOH Approval to contribute positively to the revenue of the Group during this COVID-19 pandemic / endemic period for the financial year ending 31 December 2022. However, given the ever-evolving nature of the COVID-19 pandemic / endemic where new COVID-19 related products and services are constantly being developed and launched in the market, the Company is unable to quantify such financial impact as the sales uptake of the Testing Services cannot be determined as at the date of this announcement.

Save for their respective shareholdings in the Company (if any), the Company is not aware of any of its directors or substantial shareholders having any interest, direct or indirect, in the MOH Approval.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

Song Tang Yih
Executive Director and Chief Executive Officer
29 December 2021

*This announcement has been prepared by the Company and has been reviewed by United Overseas Bank Limited (the "**Sponsor**") for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Lim Hoon Khia, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*